1. In 500 of your own words describe the benefit of designing a combination therapy of active treatment and imaging agent for use in patients with coronary artery disease.
Cardiovascular disease is the main cause of the global mortality and morbidity of 17 million people. Surgical procedures currently combating this disease are percutaneous coronary angioplasty and coronary artery bypass grafting; both risking vein graft failure or restenosis; requiring further surgical intervention, drug or gene treatment. (Thomas, 2012)
Target local drug delivery treatment (TLDD) was established to overcome systemic drug delivery complications and side effects of toxicity, high cost (repeated dosage) and low patient compliance. Also systemic gene administration …show more content…
Physicals techniques used are delivery catheter, coated stent, adventitial delivery and brachytherapy, to name a few. However, active methods used are using antibodies or targeting peptide to aim the drug at specific targets. In addition, nanoparticles have been used recently to improve the delivery and bioavailability of the active agent. (Wilensky, 2010). A nanoparticle is a particle that is less than 100nm in size and has magnetic and fluorescent material. It has a large surface area and is small enough to pass the blood brain barrier. Furthermore, nanoparticles can be used for optical imaging as a contrast agent as well as for drug delivery. (Zi Gu1, 2012).
There are future benefits of using combination therapy of active treatment and imaging for the treatment of patients with CAD. An imaging agent such as a nanoparticle is combined with drug targeting to achieve the delivery of specific drugs to an exact location. The nanocarriers that have been recognised as Therapeutic and “thernanostic”(particles integrated in diagnostic imaging and therapeutic element) agents such as polymeric nanoparticles, liposomes and cross-linked iron oxide (CLIO) particles conjugated to therapeutic molecules. (Biana Godin1, …show more content…
H. S., Rita E. Serda1, Alessandro Grattoni1, Ali Bouamrani1, Mauro, 2010, Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases: Volume 31, Issue 5, May 2010, Pages 199–205, v. 31, p. 199–205.
Groot, J. J. P. K. a. E. d., 2008, REVIEWReferences Restenosis and V Ultrasound imaging techniques for the evaluation of cardiovascular therapies: European Heart Journal, v. 29, p. 849–858.
Jaffer, F. A., P. Libby, and R. Weissleder, 2009, Optical and Multimodality Molecular Imaging Insights Into Atherosclerosis: Arterioscler Thromb Vasc Biol, v. 29, p. 1017-24.
Patrick M. Winter, A. M. N., Shelton D. Caruthers, Thomas D. Harris, J. David Robertson, Todd A. Williams, Anne H. Schmieder, Grace Hu, John S. Allen, Elizabeth K. Lacy, Huiying Zhang, Samuel A. Wickline, Gregory M. Lanza, 2006, Endothelial ανβ3 Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis: Arteriosclerosis, Thrombosis, and Vascular Biology, v. 26, p. 26: 2103-2109.
Thomas, A. C., 2012, Targeted Treatments for Research Notices, v.
Cardiovascular disease is the main cause of the global mortality and morbidity of 17 million people. Surgical procedures currently combating this disease are percutaneous coronary angioplasty and coronary artery bypass grafting; both risking vein graft failure or restenosis; requiring further surgical intervention, drug or gene treatment. (Thomas, 2012)
Target local drug delivery treatment (TLDD) was established to overcome systemic drug delivery complications and side effects of toxicity, high cost (repeated dosage) and low patient compliance. Also systemic gene administration …show more content…
Physicals techniques used are delivery catheter, coated stent, adventitial delivery and brachytherapy, to name a few. However, active methods used are using antibodies or targeting peptide to aim the drug at specific targets. In addition, nanoparticles have been used recently to improve the delivery and bioavailability of the active agent. (Wilensky, 2010). A nanoparticle is a particle that is less than 100nm in size and has magnetic and fluorescent material. It has a large surface area and is small enough to pass the blood brain barrier. Furthermore, nanoparticles can be used for optical imaging as a contrast agent as well as for drug delivery. (Zi Gu1, 2012).
There are future benefits of using combination therapy of active treatment and imaging for the treatment of patients with CAD. An imaging agent such as a nanoparticle is combined with drug targeting to achieve the delivery of specific drugs to an exact location. The nanocarriers that have been recognised as Therapeutic and “thernanostic”(particles integrated in diagnostic imaging and therapeutic element) agents such as polymeric nanoparticles, liposomes and cross-linked iron oxide (CLIO) particles conjugated to therapeutic molecules. (Biana Godin1, …show more content…
H. S., Rita E. Serda1, Alessandro Grattoni1, Ali Bouamrani1, Mauro, 2010, Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases: Volume 31, Issue 5, May 2010, Pages 199–205, v. 31, p. 199–205.
Groot, J. J. P. K. a. E. d., 2008, REVIEWReferences Restenosis and V Ultrasound imaging techniques for the evaluation of cardiovascular therapies: European Heart Journal, v. 29, p. 849–858.
Jaffer, F. A., P. Libby, and R. Weissleder, 2009, Optical and Multimodality Molecular Imaging Insights Into Atherosclerosis: Arterioscler Thromb Vasc Biol, v. 29, p. 1017-24.
Patrick M. Winter, A. M. N., Shelton D. Caruthers, Thomas D. Harris, J. David Robertson, Todd A. Williams, Anne H. Schmieder, Grace Hu, John S. Allen, Elizabeth K. Lacy, Huiying Zhang, Samuel A. Wickline, Gregory M. Lanza, 2006, Endothelial ανβ3 Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis: Arteriosclerosis, Thrombosis, and Vascular Biology, v. 26, p. 26: 2103-2109.
Thomas, A. C., 2012, Targeted Treatments for Research Notices, v.